Business Context and Reporting Period
This Form 8-K is filed by Gemini Therapeutics, Inc. (not Disc Medicine, Inc.) on November 15, 2021. The report serves to furnish the press release regarding the Company's financial results for the quarter ended September 30, 2021, which was originally announced on August 15, 2021.
Key Financial Metrics
The filing text provided is a cover page and index for the 8-K report. It references a press release (Exhibit 99.1) containing the actual financial data but does not include the specific figures within this text.
- Revenue, Profit, Cash Flow, Margins: The filing text does not provide a clear value.
- Debt and Liquidity: The filing text does not provide a clear value.
Material Changes
The filing text does not provide a clear value regarding material changes versus the prior comparable period. Investors must refer to the attached Exhibit 99.1 (Press Release) for comparative analysis.
Guidance, Outlook, and Risks
The filing text does not provide a clear value regarding guidance, outlook, management commentary, risks, or unusual items. The document explicitly states that the information in Item 2.02 and Exhibit 99.1 is "furnished" and not "filed" for purposes of Section 18 of the Securities Exchange Act of 1934.
Investor Verification Checklist
- Verify the correct registrant name is Gemini Therapeutics, Inc. (GMTX), as the input metadata incorrectly listed "Disc Medicine, Inc."
- Locate and review Exhibit 99.1 (Press Release dated November 15, 2021) to obtain actual revenue, net loss, and cash position figures.
- Note the discrepancy between the announcement date (August 15, 2021) and the filing date (November 15, 2021) for the Q3 2021 results.
- Confirm the legal status of the financial data as "furnished" rather than "filed" for liability purposes.